These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 946714)

  • 61. Suppressibility of plasma growth hormone levels in acromegaly with dexamethasone and phentolamine.
    Nakagawa K; Mashimo K
    J Clin Endocrinol Metab; 1973 Aug; 37(2):238-46. PubMed ID: 4720071
    [No Abstract]   [Full Text] [Related]  

  • 62. Effect of different dopaminergic agents in the treatment of acromegaly.
    Colao A; Ferone D; Marzullo P; Di Sarno A; Cerbone G; Sarnacchiaro F; Cirillo S; Merola B; Lombardi G
    J Clin Endocrinol Metab; 1997 Feb; 82(2):518-23. PubMed ID: 9024247
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Spontaneous hypoglycaemia in active acromegaly and its response to bromocriptine.
    Brooks AP; Stewart GW; Baird JD
    Br Med J; 1980 Apr; 280(6221):1070. PubMed ID: 6992920
    [No Abstract]   [Full Text] [Related]  

  • 64. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly.
    Wagenaar AH; Harris AG; van der Lely AJ; Lamberts SW
    Acta Endocrinol (Copenh); 1991 Dec; 125(6):637-42. PubMed ID: 1789059
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bromocriptine in acromegaly.
    Thorner MO; Besser GM; Wass JA; Liuzzi A; Hall R; Muller EE; Chiodini PG
    N Engl J Med; 1981 Oct; 305(18):1092. PubMed ID: 7278927
    [No Abstract]   [Full Text] [Related]  

  • 66. Dopaminephilic properties of ergot alkaloids.
    Goldstein M; Lew JY; Nakamura S; Battista AF; Lieberman A; Fuxe K
    Fed Proc; 1978 Jun; 37(8):2202-6. PubMed ID: 26607
    [No Abstract]   [Full Text] [Related]  

  • 67. Bromocriptine treatment over 12 years in acromegaly: effect on growth hormone and prolactin secretion.
    Rau H; Althoff PH; Schmidt K; Usadel KH
    Acta Endocrinol (Copenh); 1992 Mar; 126(3):247-52. PubMed ID: 1574954
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term bromocriptine treatment and somatostatin in acromegaly.
    Gáspár L; László FA
    Endokrinologie; 1980 Oct; 76(2):152-62. PubMed ID: 6108852
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term treatment with 2-Br-alpha-ergocryptine in acromegaly.
    Belforte L; Camanni F; Chiodini PG; Liuzzi A; Massara F; Molinatti GM; Müller EE; Silvestrini F
    Acta Endocrinol (Copenh); 1977 Jun; 85(2):235-48. PubMed ID: 405832
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Letter: Bromocritine and serum-growth-hormone levels in diabetes mellitus.
    Cassar J; Edwards R; Mashiter K; Kohner EM
    Lancet; 1975 Jul; 2(7926):181. PubMed ID: 49771
    [No Abstract]   [Full Text] [Related]  

  • 71. [Therapeutic experience with CB-154 in acromegaly].
    Abe K; Shigemasa C; Takeda A; Ikeda T; Kitahara K
    Horumon To Rinsho; 1977 Dec; 25(12):1338-40. PubMed ID: 598040
    [No Abstract]   [Full Text] [Related]  

  • 72. [Drug therapy of acromegaly using bromocriptine: results after a 1-year therapy].
    Benker G; Zäh W; Günnewig H; Hackenberg K; Werner U; Reinwein D
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1899-901. PubMed ID: 801096
    [No Abstract]   [Full Text] [Related]  

  • 73. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects.
    Halse J; Harris AG; Kvistborg A; Kjartansson O; Hanssen E; Smiseth O; Djøsland O; Hass G; Jervell J
    J Clin Endocrinol Metab; 1990 May; 70(5):1254-61. PubMed ID: 2186055
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Endocrinologic evaluation of 61 patients with acromegaly treated with transsphenoidal removal alone, or associated with telecobalt irradiation or bromocriptine or both].
    Barceló B; Pérez C; Dávila N; Lucas T; Salto L; Alcañiz J
    Med Clin (Barc); 1983 May; 80(17):735-41. PubMed ID: 6621120
    [No Abstract]   [Full Text] [Related]  

  • 75. Dopaminergic control of growth hormone secretion in normal and acromegalic subjects.
    Molinatti GM; Camanni F; Massara F; Isaia GC
    Panminerva Med; 1975 Apr; 17(4):101-6. PubMed ID: 1153217
    [No Abstract]   [Full Text] [Related]  

  • 76. Effect of bromocriptine, ergotamine and other ergot alkaloids on the hormone secretion and growth of a rat pituitary tumour.
    Prysor-Jones RA; Jenkins JS
    J Endocrinol; 1980 Jul; 86(1):147-53. PubMed ID: 7430884
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients.
    Fedele D; Molinari M; Meneghel A; Valerio A; Muggeo M; Tiengo A
    J Endocrinol Invest; 1980; 3(2):149-53. PubMed ID: 6993548
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Factors determining the effectiveness of CB-154 in the treatment of acromegaly.
    Hanew K; Sasaki A; Sato S; Shimizu Y; Murakami O; Yoshinaga K
    Tohoku J Exp Med; 1983 Jan; 139(1):91-5. PubMed ID: 6404005
    [No Abstract]   [Full Text] [Related]  

  • 79. [Growth hormone secretion in relation to changes in thyrotropic hormone after thyroliberin in patients with acromegaly and dopaminergic stimulation (author's transl)].
    Felt V; Nedvídková J
    Cas Lek Cesk; 1982 Apr; 121(16):489-93. PubMed ID: 6807547
    [No Abstract]   [Full Text] [Related]  

  • 80. Response of acromegaly to long term bromocriptine therapy: a biochemical and clinical assessment.
    Clayton RN; Vrionides Y; Lynch SS; Butt WR; London DR
    Acta Endocrinol (Copenh); 1978 Nov; 89(3):469-82. PubMed ID: 360752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.